Coding · November 13, 2026

Basal Cell Carcinoma ICD-10 Codes (C44.x): How to Code BCC for Dermatology Billing

Basal cell carcinoma ICD 10 codes sit in category C44, with a fifth character of 1 for basal cell and site characters such as C44.311 for the nose. This guide covers BCC codes by site, how they differ from SCC and melanoma, holding charges until pathology, linking C44 to Mohs, excision and repair lines, and when Z85.828 replaces the active code.

This article is part of the dermatology billing blog, where we cover coding, denials and payer policy as they change.

TRWritten by , CEO of DermBillingUSAPublished Updated 18 min read
In this guide
  1. How Is a Basal Cell Carcinoma ICD 10 Code Built?
  2. Most Used Basal Cell Carcinoma ICD 10 Codes by Site
  3. How Do BCC Codes Differ From SCC, Melanoma, In Situ and Uncertain Behavior Codes?
  4. Should You Hold Charges Until the Pathology Report Is Back?
  5. How Does the C44 Code Link to Mohs, Excision, Destruction and Repair?
  6. Worked Example: From BCC Biopsy to Mohs With the Diagnosis on Each Line
  7. History of Basal Cell Carcinoma: Z85.828 vs Active C44 Codes
  8. Original Medicare, Medicare Advantage and Commercial Plans: What Differs for BCC Claims
  9. Which ICD-10-CM Code Set Applies to Your BCC Claims?
  10. Common BCC Coding Mistakes and the Denials They Cause
  11. Get Your BCC Claims Checked Against the Pathology Report
  12. Sources
  13. Frequently Asked Questions
  14. Want this checked against your own claims?
Basal cell carcinoma ICD 10 coding guide cover showing the C44.x1 code pattern for dermatology billing
How C44 basal cell carcinoma codes are built and linked to biopsy, Mohs, excision and repair claims.

Quick answer: Basal cell carcinoma ICD 10 codes sit in category C44. Each code combines a body site, a fifth character of 1 that marks basal cell, and laterality where the site has it, such as C44.311 for the nose and C44.41 for the scalp and neck. Report C44.91 only when no site is documented, and code from the final pathology report.

A basal cell carcinoma (BCC) claim can fail in one of three places. The diagnosis names no site, the site on the pathology report does not match the operative note, or the charge left the building before the pathology report came back. Any of the three gives a payer a reason to question a Mohs or excision line that was routine on the clinical side.

The fiscal year (FY) 2027 diagnosis code set has applied to encounters since October 1, 2026, according to the CMS ICD-10 page. This guide is for dermatology coders, billers and practice managers, and it supports our dermatology coding services. It follows one lesion from biopsy to Mohs, with the diagnosis on every claim line.

How Is a Basal Cell Carcinoma ICD 10 Code Built?

A BCC code starts with C44, adds a body-site character, then a fifth character of 1 for basal cell, then laterality or site-part characters where the tabular list requires them.

C44 is the ICD-10-CM category for other and unspecified malignant neoplasms of skin. ICD-10-CM is the Clinical Modification of the International Classification of Diseases, 10th Revision, the diagnosis code set that every HIPAA-covered payer uses. Squamous cell carcinoma (SCC) shares the category and takes a fifth character of 2, so one wrong digit turns a BCC claim into an SCC claim.

Reading Two Codes Character by Character

Two examples show how the characters stack up.

  • C44.311: C44 is the category, 3 is the face group, 1 marks basal cell, and the final 1 is the nose.
  • C44.1121: C44 is the category, 1 is the eyelid group, 1 marks basal cell, 2 is the right side, and the final 1 is the upper eyelid.
How two basal cell carcinoma codes break down, character by character.

A coder who knows this pattern can catch a bad code in seconds. A charge for a BCC that carries a 2 in the fifth position reads as SCC.

Why Unspecified-Site Codes Cause Trouble

C44.91 reports a BCC with no site, and it belongs on a claim only when the record truly has no site. Excision, destruction, Mohs and repair codes are all chosen by anatomic location, so a diagnosis with no site cannot be checked against the procedure line.

Chapter III of the Medicare NCCI Policy Manual tells providers to report the procedure code to the greatest specificity possible. Hold the diagnosis to the same standard. When the operative note names the nose and the claim says C44.91, the fix is a short provider query, not a default code.

Most Used Basal Cell Carcinoma ICD 10 Codes by Site

The most used BCC codes run from C44.01 for the lip to C44.91 for an unspecified site, with C44.311 for the nose and C44.41 for the scalp and neck among the most specific.

BCC code families by skin site, FY 2027 ICD-10-CM. Confirm each code in the CMS 2027 code descriptions before loading a picklist.

Body siteBCC codeLaterality or partNote
LipC44.01NoneSkin of the lip
Eyelid, including canthusC44.111, C44.1121, C44.1122, C44.1191, C44.1192Unspecified; right upper and lower; left upper and lowerPick side and lid from the note
Ear and external auricular canalC44.211, C44.212, C44.219Unspecified, right, leftLeft side ends in 9
NoseC44.311NoneOwn code within the face group
Other parts of faceC44.319NoneFace sites outside the nose, lip, ear and eyelid
Scalp and neckC44.41NoneOne code covers both
TrunkC44.519Other part of trunkBreast skin and anal skin take a different sixth character
Upper limb, including shoulderC44.61 plus a sixth characterUnspecified, right or leftChoose the side from the note
Lower limb, including hipC44.71 plus a sixth characterUnspecified, right or leftChoose the side from the note
Overlapping sitesC44.81NoneOne lesion crossing two site groups
Unspecified siteC44.91NoneUse only when no site is documented

Build the charge-entry picklist from the site column, not from a free-text search. A coder who types "basal cell" into a search box can land on a code for the wrong eyelid or the wrong limb, and the screen will not complain.

How Do BCC Codes Differ From SCC, Melanoma, In Situ and Uncertain Behavior Codes?

BCC and SCC share category C44 and differ by the fifth character, melanoma is C43, carcinoma in situ of skin is D04, and neoplasms of uncertain or unspecified behavior use D48.5 and D49.2.

The pathology wording decides the category. A coder does not pick between C44, D04 and D48.5 from the clinical impression.

Skin diagnosis families a dermatology coder meets after a biopsy.

Pathology resultCode familyNote
Basal cell carcinomaC44.x1Fifth character 1; C44.311 for the nose
Squamous cell carcinomaC44.x2Same site digits as BCC, fifth character 2
MelanomaC43Separate category, never C44
Merkel cell carcinomaC4ASeparate category
Melanoma in situD03In situ melanoma stays out of C43
Carcinoma in situ of skinD04Not C44
Benign neoplasm of skin, nevusD22, D23Pairs with benign procedure codes
Uncertain behaviorD48.5The report says behavior cannot be determined
Unspecified behaviorD49.2No behavior stated

A D48.5 or D49.2 code should be temporary. If the final report names a BCC, replace the uncertain code before the claim goes out. If the report gives an addendum days later, the diagnosis on a claim already sent needs a correction.

Should You Hold Charges Until the Pathology Report Is Back?

Yes. Hold the biopsy charge and any excision charge until the final pathology report is in the chart, because the diagnosis code and the benign or malignant procedure family both depend on that result.

Dermatopathology bench with labeled skin specimens, stained slides and a pathology report awaiting BCC coding
The final pathology report decides the C44 code and the benign or malignant procedure family. Illustrative, AI-generated.

The outpatient section of the FY 2027 ICD-10-CM Official Guidelines has its own rule for uncertain diagnoses. In an outpatient setting, a "suspected" or "probable" diagnosis is not reported as confirmed. Until pathology confirms a BCC, only the documented findings are coded.

The same logic splits excision codes. The Medicare NCCI Policy Manual lists excision of benign lesions under 11400 to 11471 and excision of malignant lesions under 11600 to 11646. The pathology result decides which family fits the specimen.

Here is a hold workflow a front-end team can follow:

  1. Biopsy the lesion and record the exact site, side and lesion count in the procedure note.
  2. Place the charge on hold with a reason of "pathology pending".
  3. Match the incoming pathology report to the chart and the specimen.
  4. Ask the provider to document the result in the visit note, so the diagnosis comes from the provider's record and not from the lab report alone.
  5. Assign the C44 code from the pathology wording, then release the charge.

Suppose the biopsy charge goes out on the day of the procedure with a lesion code, and the report then reads BCC. That forces a corrected claim and a second review of every later line for that lesion. Our guide to holding excision charges until pathology covers the hold rules in depth. For the lab side, see our dermatopathology billing guide.

The C44 code goes on every line that treats the BCC, and it must match the site in the operative note. Chapter III of the Medicare NCCI Policy Manual, revised January 1, 2026, sets the rules for combining those lines.

Sterile Mohs surgery instrument tray with a tissue mapping sheet in a dermatology procedure room
Every Mohs, excision and repair line for the same BCC carries the same site-specific C44 code. Illustrative, AI-generated.

Procedure families that take a C44 diagnosis, with the Medicare NCCI point for each (Chapter III, revision date January 1, 2026).

Procedure familyCPT code numbersDiagnosis to linkNCCI point
Skin biopsy11102-11107Path-confirmed C44 codeIncluded in removal of the same lesion at the same encounter
Excision, benign lesions11400-11471A benign code, not C44Repairs of 0.5 cm or less excisions are not separate
Excision, malignant lesions11600-11646C44 code for the siteIntermediate and complex repairs may be reported
Destruction, benign or premalignant17000, 17004A benign or premalignant code, not C44Paired with biopsy codes by NCCI edits
Destruction, malignant17260-17286C44 code for the siteOne removal code per lesion
Mohs surgery17311-17315C44 code for the siteIncludes biopsy, excision and pathology services
Repair, flaps and grafts12001-13160, 14000-14350Same C44 code as the removal lineSimple repair is part of lesion removal

Mohs Surgery

NCCI describes Mohs micrographic surgery as the removal of a complex or ill-defined cutaneous malignancy, with one physician doing both the surgery and the pathologic examination. The Mohs codes include skin biopsy and excision services and surgical pathology, so those codes are not reported in addition to the Mohs codes.

A diagnostic biopsy before Mohs is the exception. NCCI allows the biopsy and frozen section code 88331 to be reported with modifier 59, XS or XU, or with modifier 58 for a planned, staged procedure. Repairs, grafts and flaps are separately reportable with Mohs. Our Mohs surgery billing guide shows how stages and blocks are counted.

NCCI also allows only one unit of 88342 per specimen for an initial antibody stain, with 88341 added for each different antibody stain. The unit is the specimen, not each block.

Malignant Excision

NCCI allows only one removal code per lesion, and removal includes the biopsy of the same lesion at the same encounter. Biopsy codes 11102 to 11107 may be separate only when the biopsy was on a different lesion from the removal.

Closure rules decide how many lines the claim carries. Simple repair codes 12001 to 12021 are part of lesion removal. Intermediate or complex repairs, adjacent tissue transfer and grafts may be reported when medically reasonable and necessary. Adjacent tissue transfer includes the excision, so 11600 to 11646 are not reported separately with it for the same lesion.

Destruction

BCC destruction belongs in the malignant destruction range, 17260 to 17286, and not in 17000 or 17004, which NCCI describes as destruction of benign or premalignant lesions. Linking C44 to 17000 or 17004 sends a mismatch the payer can see. Our lesion destruction coding guide covers counts and units.

NCCI also pairs biopsy codes 11102, 11104 and 11106 with 17000 and 17004. Modifier 59, XE or XS is appropriate only when the two services were on separate lesions or at separate encounters.

Repair, Flaps and Grafts

Repair lines carry the same C44 code as the excision or Mohs line they close. For a Mohs defect, NCCI allows simple, intermediate and complex repairs to be reported with 17311 to 17315. For an excision of a benign lesion of 0.5 cm or less, NCCI includes the repair in the excision.

Worked Example: From BCC Biopsy to Mohs With the Diagnosis on Each Line

A hypothetical Original Medicare patient has a nose lesion biopsied on October 5, 2026. Pathology returns on October 8, and Mohs follows on October 26, which is 21 days after the biopsy. Every date falls in the FY 2027 code set.

The codes below illustrate the pattern. A real coder selects them from the operative note and the pathology report, and nothing in this example is a clinical recommendation.

  1. October 5, 2026: the provider biopsies the lesion and documents the nose as the site. The practice places the charge on hold.
  2. October 8, 2026: the pathology report returns with a BCC diagnosis, 3 days after the biopsy. The provider documents the result in the chart.
  3. Release the biopsy charge: the coder assigns C44.311 and releases the biopsy line with that diagnosis.
  4. October 26, 2026: the Mohs surgeon removes the BCC in 2 stages and closes the defect. Every line carries C44.311.
  5. Check the claim: the coder confirms the code set, the site and the side match across both dates before release.
The worked example from biopsy to Mohs, with C44.311 on every line. Hypothetical patient.

Claim lines for the example, with the diagnosis pointer on each line.

Date of serviceLineCodeDiagnosis on the lineNote
October 5, 2026111102C44.311Released after the October 8, 2026 report
October 5, 2026288305C44.311Billed by whoever interprets the slides; your claim only with an in-house lab
October 26, 2026117311C44.311First Mohs stage
October 26, 2026217312C44.311Second Mohs stage
October 26, 2026312051C44.311Intermediate repair, separately reportable with Mohs

The biopsy and the Mohs surgery fall on different dates, so no modifier 59, XS, XU or 58 is needed to separate them. NCCI procedure-to-procedure (PTP) edits are based on services by the same physician on the same date of service. Had the biopsy and Mohs happened the same day, the modifiers in the Mohs section above would apply.

Consider what goes wrong. If the biopsy line had gone out on October 5 with C44.91, and the Mohs claim carried C44.311, the same lesion would carry two different diagnoses on two claims. An office visit on the biopsy date takes modifier 25 only when it is separately identifiable, and NCCI says the visit and the minor procedure do not need different diagnoses. Our skin biopsy coding guide explains when that visit is billable.

*Diagnosis codes not matching your Mohs and excision claims?* The request form for a [free claims audit](https://dermbillingusa.com/free-dermatology-claims-audit) is near the end of this guide, under "Get Your BCC Claims Checked Against the Pathology Report".

History of Basal Cell Carcinoma: Z85.828 vs Active C44 Codes

Z85.828, personal history of other malignant neoplasm of skin, replaces the C44 code only after the BCC has been excised or eradicated and no evidence of it remains at that site. While treatment is still directed at the site, the C44 code stays.

Dermatologist typing follow-up visit notes that document whether a treated basal cell carcinoma site is clear
The provider's note on whether the site is clear decides between Z85.828 and an active C44 code. Illustrative, AI-generated.

The FY 2026 ICD-10-CM Official Guidelines state both halves of the rule in section I.C.2. A Z85 code is used when a primary malignancy was excised or eradicated with no evidence at that site. When further treatment, such as another surgery or radiation, is directed to the site, the primary malignancy code is used until treatment is complete. The FY 2027 guidelines linked above apply to encounters from October 1, 2026, so re-read Section I.C.2 there.

Which code fits which BCC encounter.

SituationCode to reportReason
BCC confirmed, treatment not yet doneC44 code for the siteThe cancer is active
Mohs stage or further surgery directed at the siteC44 code for the siteTreatment is still under way
Follow-up visit after completed treatment, no evidence at the siteZ08 with Z85.828History of skin cancer; follow-up after treatment
New BCC at a different siteNew C44 code for the new siteA separate primary lesion
Screening skin check with no complaintZ12.83 firstSee our skin cancer screening coding guide

Z08 is the encounter for a follow-up exam after completed treatment for a malignant neoplasm. Z85.828 covers other malignant neoplasms of skin, such as BCC, and Z85.820 is the melanoma history code.

What goes wrong: coders leave the C44 code on every follow-up visit because it is already on the problem list. If the provider documents that the site is clear, the claim should carry the history code. The reverse error also happens, when Z85.828 sits on a claim for a lesion that has just been re-biopsied and read as BCC.

Original Medicare, Medicare Advantage and Commercial Plans: What Differs for BCC Claims

The ICD-10-CM code is the same for every payer, but the edits, diagnosis lists and policy documents differ by payer type, so each claim follows its own payer's rules.

CMS states that ICD-10 applies to all parties covered by the Health Insurance Portability and Accountability Act (HIPAA), not only providers who bill Medicare or Medicaid. A C44.311 on a commercial claim means the same thing as on a Medicare claim. What changes is who enforces which edit.

Who sets the rules for BCC claims by payer type.

Payer typeWho sets the rulesWhat to check before billing
Original Medicare (Part B)CMS, through the NCCI Policy Manual for Medicare effective January 1, 2026NCCI Chapter III edits; your Medicare Administrative Contractor (MAC) for claim-specific questions and appeals
Medicare AdvantageThe plan, through its provider manual and coding policiesThe plan's Mohs and excision policy and any authorization rule
CommercialEach payer's own policyThe payer's Mohs and excision policy, modifier rules and diagnosis lists
MedicaidThe state program; CMS publishes a separate Medicaid NCCI manualThe state's billing manual and the Medicaid NCCI Chapter III with a January 1, 2026 revision date

The CMS NCCI for Medicare page says claim-specific inquiries and appeals go to the MAC, and that the NCCI program cannot answer questions about other payors or about local coverage determinations. A local coverage determination (LCD) is a MAC's own coverage rule, and it can attach diagnosis requirements to Mohs. This guide uses CMS national sources only, so check your MAC's LCD and billing articles before you finalize a Mohs diagnosis list.

Which ICD-10-CM Code Set Applies to Your BCC Claims?

Encounters from October 1, 2026 through September 30, 2027 use the FY 2027 ICD-10-CM code set. The date of service picks the code set, not the date the claim is sent.

ICD-10-CM code set by encounter date, per the CMS ICD-10 page.

Encounter datesCode setFiles to use
October 1, 2025 to March 31, 2026FY 2026 October release2026 files
April 1, 2026 to September 30, 2026FY 2026 April updateApril 1, 2026 files
October 1, 2026 to September 30, 2027FY 20272027 files

CMS publishes a 2027 addendum that lists added, deleted and revised codes, plus a 2027 conversion table. Run your BCC picklist against the addendum before it goes live, and check older files in the CMS ICD-10 files archive for claims with earlier dates of service. The documentation trade group ACDIS reported that the FY 2027 guidelines revised several areas, including cancer treatment and Z codes, which are the two areas this guide leans on. Our dermatology coding updates page tracks the changes that touch dermatology.

Common BCC Coding Mistakes and the Denials They Cause

BCC claims run into trouble where the diagnosis disagrees with the procedure line or with the pathology report. Each mistake below has a fix a coder can apply before release.

Billing specialist highlighting an operative note while checking a basal cell carcinoma claim for diagnosis mismatches
Comparing the operative note with the claim catches site and laterality errors before release. Illustrative, AI-generated.

BCC coding mistakes, the denial they can trigger and the fix.

MistakeWhy it failsPossible denial or editFix
C44.91 on a Mohs or excision lineNo site to match the procedureClaim adjustment reason code (CARC) 11, diagnosis inconsistent with the procedureQuery the provider for the site in the operative note
SCC fifth character on a BCCHistology and code disagree with the reportRecord request; mismatch with the pathology claimCode from the report wording, not the clinical impression
"Suspected BCC" coded as C44 before pathologyOutpatient rules do not report uncertain diagnoses as confirmedCorrected claim laterHold the charge until the report returns
C44 linked to 17000 or 17004Those codes describe benign or premalignant destructionCARC 11 or CARC 50, not medically necessaryUse the malignant destruction range for a BCC
Biopsy billed with excision of the same lesionRemoval includes the biopsy of that lesionCARC 97, benefit included in another serviceDrop the biopsy line; keep it only for a different lesion
Biopsy and Mohs on one date with no modifierNCCI pairs them; the modifier signals a staged diagnostic biopsyNCCI edit denialAdd modifier 59, XS, XU or 58 as NCCI allows
Z85.828 on an active site, or C44 on a cleared siteThe status of the cancer decides the codeMedical necessity reviewApply the Z85 rule from the guidelines
Wrong side or lid on an eyelid or ear codeLaterality is part of the codeRecord request or audit findingCheck the side against the operative note

Match each denial to its remittance code in our dermatology denial codes index. Each payer words its denials differently, so treat the third column as what can happen, not what always happens.

Insider tip: pull a list of every claim that carried C44.91 in the last quarter and compare it with the operative notes. Each hit is a coding or documentation gap you can close at the source.

Get Your BCC Claims Checked Against the Pathology Report

Diagnosis codes not matching your Mohs and excision claims? DermBilling USA codes dermatology claims for dermatology, dermatopathology and Mohs practices. A free claims audit reviews a de-identified sample of your claims and returns a line-item report on coding gaps and denial causes.

Request a free claims audit

Signs your BCC claims need a second look:

  • Biopsy charges leave the practice before pathology returns.
  • Mohs and excision lines carry C44.91 or a site that differs from the operative note.
  • Repair lines deny while the excision lines pay.
  • Follow-up visits carry active C44 codes after treatment is complete.

Never send patient names, dates of birth or other protected health information through the request form.

Sources

This guide is a billing reference, not legal or coding advice for a specific claim. Check your MAC and each payer's current policy before billing.

Primary sources

Coding and coverage rules change. Verify against the source before you bill.

Where this sits in our reference library

The evergreen pages behind this article, kept current as payer policy moves.

/ FAQs

Frequently Asked Questions

No single code covers it. BCC codes begin with C44, carry a fifth character of 1, and add the site, such as C44.311 for the nose or C44.41 for the scalp and neck. C44.91 is the code for a BCC with no documented site.

C44.311. The fifth character 1 marks basal cell, and the final 1 places the lesion on the nose. Confirm the code in the CMS 2027 tabular files before loading it into a picklist.

Yes, but only when the record gives no site. When the operative note or pathology requisition names a site, a site-specific C44 code is the right choice, and the claim should be held while the provider is queried.

No. A suspected BCC is not reported as confirmed in the outpatient setting. Hold the charge until the final report is in the chart, then code the result.

Z85.828 reports a personal history of other malignant neoplasm of skin. Use it when the BCC was excised or eradicated and no evidence remains at the site, and add Z08 for a follow-up visit after completed treatment.

Yes. Each line that treats or closes the same BCC points to the same site-specific C44 code. A line for a different lesion points to the code for that lesion's own site.

No. The ICD-10-CM code is the same for every HIPAA-covered payer. The plan's own edits, diagnosis lists and authorization rules are what differ, so check each payer's Mohs and excision policy.

Want this checked against your own claims?

A free claims audit reviews a de-identified sample of your dermatology claims and returns a line-item findings report showing where the issues in this article are costing you money.

Request a free dermatology claims audit →

About the Author

TR

CEO of DermBillingUSA

Touseef Riaz is CEO of DermBillingUSA and writes about dermatology practice revenue cycle management, billing operations, and business performance.

LinkedIn

Find your leaked revenue. Free dermatology claims audit — results in 5 business days.